SK Chemicals announced on August 13 that it recorded a second-quarter revenue of 479.1 billion won and an operating profit of 31.9 billion won, according to its separate financial statements.
The revenue represents a 24.8% increase compared to the same period last year, marking the highest quarterly sales since the company was split into a business entity following the launch of SK Discovery in 2017. Operating profit also rose by 26.8% from the second quarter of last year, driven by stable demand for Green Chemicals and strong sales in the pharmaceutical sector, resulting in balanced growth across all business divisions.
SK Chemicals focuses on the development, production, and sales of copolyesters and high-performance materials, as well as synthetic drugs, natural products, and biopharmaceuticals.
An SK Chemicals official stated, "Despite ongoing uncertainties both domestically and internationally, we continue to maintain a steady growth trajectory centered on our core businesses. In the second half of the year, we plan to expand sales of high-value products in the Green Chemicals sector and enhance our product pipeline in pharmaceuticals while diversifying treatment areas."
Meanwhile, including its subsidiary SK Bioscience, SK Chemicals reported consolidated revenue of 745.1 billion won and an operating profit of 32.3 billion won for the second quarter, marking a return to profitability.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.